Celgene Corporation and BeiGene, Ltd. Company Profile

12:37 EDT 19th September 2018 | BioPortfolio

News Articles [720 Associated News Articles listed on BioPortfolio]

Celgene-Partner BeiGene drückt auf die Tube: Aktie vor Kaufsignal

In China treibt der Celgene-Parner BeiGene die weltweite Entwicklung des Flaggschiffproduktes Tislelizumab weiter voran und befindet sich weiter auf Kurs. Dieser Ansicht sind auch die Analysten der...

Celgene-Partner BeiGene mit News im Doppelpack - Aktie vor Kaufsignal

Die Biotech-Gesellschaft BeiGene musste zuletzt kräftig Federn lassen. Dies könnte sich allerdings schlagartig ändern: Tislelizumab, bei dem sich Celgene für 1,4 Milliarden Dollar eingekauft hat, ...

Celgene-Partner BeiGene: Verleiht der China-IPO Schwung?

BeiGene hat sich für das Zweitlisting an der Börse in Hong Kong einen denkbar ungünstigen Zeitpunkt ausgesucht. In China macht ein Impfstoff-Skandal die Runde und belastet die Kurse von Pharma- und...

BeiGene Starts China Phase III Trial of PD-1 Drug in Squamous NSCLC

BeiGene, a Beijing oncology biopharma, has dosed the first patient in a China Phase III trial of its PD-1 antibody as a first-line treatment for lung cancer. According to BeiGene's count, the trial is...

BeiGene Reports Positive PD-1 Data; Plans China NDA Filing This Year

Beijing's BeiGene reported positive top-line results from a China pivotal Phase II trial of its PD-1 candidate in patients with classical Hodgkin's lymphoma. The drug produced a 73% overall response a...

BeiGene Initiated Global Phase II Clinical Trial for PD-1 Antibody

BeiGene announced the initiation of a multi-center Phase II clinical trial of tislelizumab, an anti-PD-1 antibody, in patients with previously treated advanced hepatocellular carcinoma (HCC or liver c...

BeiGene and SpringWorks to Pair RAF and MEK Inhibitors in Solid Tumor Combo

BeiGene, a Beijing novel oncology company, will collaborate with New York's SpringWorks Therapeutics, combining BeiGene’s RAF inhibitor with SpringWorks' MEK inhibitor to treat patients with adv...

BeiGene and SpringWorks enter trial collaboration for solid tumors

BeiGene Ltd. and SpringWorks Therapeutics partnered to evaluate the combination of BeiGene’s lifirafenib (GBG283) with SpringWorks’ PD0325901 as a new treatment regimen for solid tumors.

PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma.

Orlowski has received research funding from Amgen, BioTheryX, Bristol-Myers Squibb, Celgene Corporation, and Takeda Pharmaceuticals; honoraria from Amgen, Bristol-Myers Squibb, Celgene Corporation, Ja...

Clinical Trials [10 Associated Clinical Trials listed on BioPortfolio]

Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells

This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult subjects exposed to Gene-modified (GM) T cell therapy participating in a p...

Multi-center, Survival Data Collection in Subjects Previously Enrolled in Celgene Protocol CC-5013-MDS-003

Multi-center, survival data collection in subjects previously enrolled in Celgene Protocol CC-5013-MDS-003.

A Study to Evaluate Long-term Safety in Subjects With Solid Tumors and Hematological Disorders.

Rollover study supporting solid tumor and hematological disorder indications from Celgene sponsored CC-486 protocols eligible for participation in the study.

Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting Syndrome

To allow patients with HIV-associated wasting to receive thalidomide treatment at 1 of 2 doses. To gain safety and efficacy data from a broader base of patients with HIV-associated wasting...

Spondylitis Trial of Apremilast for Better Rheumatic Therapy

Presently, there are very few treatments available which affect the progression of the disease in the spine. The only proven treatment is the use of drugs inhibiting tumour necrosis factor...

Companies [197 Associated Companies listed on BioPortfolio]

Celgene Corporation and BeiGene, Ltd.

BeiGene (Beijing), Co., Ltd.

BeiGene is an innovative Chinese oncology R&D company focusing on discovering, developing and commercializing targeted and immune-oncology therapeutics. With a team of 150 scienti...

BeiGene Ltd.

BeiGene is an innovative, clinical-stage Chinese oncology R&D company focused on discovering, developing and commercializing targeted and immune-oncology therapeutics through a no...

BeiGene, Ltd.

BeiGene is a Chinese life sciences biotechnology company based in the Zhongguancun Life Science Park in Beijing that is focused on discovering and developing innovative oncology d...

Celgene International Sàrl

Celgene International Sàrl, located in Boudry, in the Canton of Neuchâtel, Switzerland, is a wholly owned subsidiary and international headquarters of Celgene Corporation. C...

More Information about "Celgene Corporation and BeiGene, Ltd." on BioPortfolio

We have published hundreds of Celgene Corporation and BeiGene, Ltd. news stories on BioPortfolio along with dozens of Celgene Corporation and BeiGene, Ltd. Clinical Trials and PubMed Articles about Celgene Corporation and BeiGene, Ltd. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Celgene Corporation and BeiGene, Ltd. Companies in our database. You can also find out about relevant Celgene Corporation and BeiGene, Ltd. Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record